Limitations of Using a Single Postdose Midazolam Concentration to Predict CYP3A‐Mediated Drug Interactions

@article{Penzak2008LimitationsOU,
  title={Limitations of Using a Single Postdose Midazolam Concentration to Predict CYP3A‐Mediated Drug Interactions},
  author={Scott R. Penzak and Kristin H. Busse and Sarah M. Robertson and Elizabeth Formentini and Raul M. Alfaro and Richard T Davey},
  journal={The Journal of Clinical Pharmacology},
  year={2008},
  volume={48}
}
Midazolam is a common probe used to predict CYP3A activity, but multiple blood samples are necessary to determine midazolam's area under the concentration‐time curve (AUC). As such, single sampling strategies have been examined. The purpose of this study was to assess the ability of single midazolam concentrations to predict midazolam AUC in the presence and absence of CYP3A modulation by Ginkgo biloba extract (GBE). Subjects received oral midazolam 8 mg before and after 28 days of GBE… Expand
Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies
TLDR
A four-sampling point limited sampling strategy to predict the oral midazolam AUC for CYP3A phenotyping is proposed after three drug interaction studies in the categories of strong, moderate, and mild induction, as well as no interaction. Expand
Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam
TLDR
The determination of the partial AUC using four plasma samples from 2 to 4 h after oral administration of a midazolam solution is proposed to be an easy and reliable CYP3A phenotyping measure which of course needs to be validated in prospective clinical trials. Expand
Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach
TLDR
A 4‐hour, but not the 1‐, 2‐, and 6-hour, single concentration accurately estimated midazolam area under the curve during constitutive CYP3A conditions in healthy adults. Expand
Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping
TLDR
Midazolam partial AUCs were unable to estimate CYP3A activity during the evaluated baseline and inhibitory conditions, and the same equations predicted the extent of CYP 3A induction as a lack of equivalence was observed with AUC0-4 and AUC1-4. Expand
Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults
TLDR
Development of a single– or 2–time point midazolam limited sampling model for general, widespread use to simultaneously evaluate various CYP3A conditions remains elusive. Expand
The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
TLDR
Results indicate that ticagrelor can weakly activate the metabolism of midazolam to its major 1'-hydroxy metabolite, and at the same time, seems to weakly inhibit midAZolam 4'-hydroxylation. Expand
Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy
TLDR
Recovery of CYP3A activity occurred with a half‐life of 24 h after voriconazole, whereas ritonavir inhibition was still strong 3 days after discontinuation, underscore the substantial and gradual alterations in dose requirements in the first days of and after such combination therapies. Expand
"In-vivo" phenotyping of CYP3A using midazolam as probe drug : development of novel approaches based on highly sensitive LC-MS/MS methods
Cytochrome P450 (CYP) 3A is the most important subfamily of drug-metabolizing enzymes in humans, responsible for metabolizing more than 50% of the currently marketed drugs. Many studies onExpand
CYP3A activity: towards dose adaptation to the individual
TLDR
Investigation into the clinical routine necessitates further research to identify an easy-to-use and cheap test for CYP3A activity that adequately predicts drug exposure to allow a sound decision on dose adaptation and hence improve clinical outcome and/or reduce the intensity or frequency of adverse drug effects. Expand
Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil
TLDR
Results show that concurrent administration of oral deuterated and i.v. ALF, either sequentially or simultaneously, is an efficient and effective approach to assessing hepatic and intestinal CYP3A activity. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 14 REFERENCES
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.
TLDR
It is concluded that a single 4-h midazolam concentration following IV or oral administration represents an accurate marker of CYP3A phenotype under constitutive and modified states and the single-point approach offers an efficient means to phenotype and identify individuals with important genetic polymorphisms that affect CYP2A activity. Expand
Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques
TLDR
Minimized plasma sampling may provide a simpler method for estimating midazolam AUC for CYP3A phenotyping and is more convenient and cost‐effective than standard sampling strategies and is applicable to more than one assay technique. Expand
Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity
TLDR
A low oral dose of midazolam can be used to measure the in vivo CYP3A activity, either by the determination of total 1′OH-midZolam/midazol am ratios at 30 min or by thedetermination of midAZolam plasma levels between 1.5 h and 4 h after its administration. Expand
Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers
TLDR
Despite the small sample size, based on the results of healthy, elderly volunteers, a single MDZ plasma measurement taken at 6 h post-oral administration may represent an accurate marker of CYP3A phenotype. Expand
Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects
TLDR
It is determined that single sampling of 1′‐hydroxymidazolam or 1‐ Hydroxyzolam: midazololam plasma concentrations cannot be used to predict midAZolam clearance in healthy adults. Expand
Influence of Food on Midazolam Absorption
TLDR
In ingestion of midazolam within one hour after a meal may result in a delay in the onset of the pharmacologic effect, and changes in the Cmax, tmax, and AUC parameters for both midAZolam and its metabolite may be of some clinical significance. Expand
Midazolam kinetics
TLDR
The effect‐kinetics of the new benzodiazepine midazolam was evaluated in six subjects after single oral and intravenous doses and infusion programs, and good intraindividual linear correlations were found between plasma levels and dynamic effects. Expand
Single‐point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam
TLDR
This investigation tested the hypothesis that a single concentration measurement can accurately predict alfentanil clearance and compared limited sampling results for alfENTanil and midazolam. Expand
Response to Nafziger and Bertino
TLDR
Reanalysis of the data in the previous study revealed significant correlations between plasma concentrations of MDZ from 30 to 120 min and its AUC, as well as between 1-OH MDZ/MDZ and MDZ clearance at various time points as described previously; however, it did not improve the r-value. Expand
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.
TLDR
Despite the limitations of many currently available probes, with continued research, phenotyping will become an even more valuable research and clinical resource. Expand
...
1
2
...